StockNews.AI
ALGS
StockNews.AI
6 days

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

1. Aligos initiated dosing in Phase 2 B-SUPREME study for chronic HBV. 2. ALG-000184 shows promising early data for chronic HBV treatment. 3. Study expects interim results in 2026 and topline in 2027. 4. Chronic HBV affects 254 million worldwide, indicating high unmet need. 5. Current therapies are inadequate, leading to liver disease and cancer.

9m saved
Insight
Article

FAQ

Why Bullish?

The positive progress in clinical studies can drive investor confidence. Historical examples like Gilead's Harvoni show significant market responses to similar advancements.

How important is it?

Investors will likely view clinical advancements favorably, especially given the disease's prevalence and lack of effective treatments.

Why Long Term?

The full impact will be realized post-study results; optimism will build as data emerges. Past biotech cases suggest stock appreciation leading up to major trial results.

Related Companies

GILDVIRTUALABBV
August 13, 2025 08:30 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection. “Despite available treatments for chronic HBV infection, better therapies are needed to stem the progression to end-stage liver disease and liver cancer,” said Nezam Afdhal, MD, DSc, Chief of Gastroenterology, Hepatology, and Nutrition at Beth Israel Deaconess Medical Center and Charlotte & Irving Rabb Distinguished Professor of Medicine at Harvard Medical School. “I am pleased that therapies such as Aligos’ ALG-000184 are continuing to progress. The impressive antiviral activity seen in clinical trials to date provides hope for patients in need.” “Dosing the first subjects in our Phase 2 B-SUPREME study is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. “We are pleased by the engagement of the clinicians and subjects, as they recognize the need for improved treatment regimens for chronic HBV infection. We believe that ALG-000184 has first/best-in-class potential based on the exciting data seen across viral markers of HBV to date. We look forward to continuing to advance ALG-000184 for patients in need of better outcomes.” The Phase 2 B-SUPREME study (NCT06963710) is a randomized, double-blind, active-controlled multicenter study evaluating the safety and efficacy of ALG-000184 monotherapy compared with tenofovir disoproxil fumarate in approximately 200 untreated HBeAg+ and HBeAg- adult subjects with chronic HBV infection for 48 weeks. The primary endpoint in the HBeAg+ part will be HBV DNA

Related News